Oncogenic pathway signatures predict the risk of progression and recurrence in well‐differentiated pancreatic neuroendocrine tumors
Well-differentiated pNETs are genomically diverse tumors. Pathway signatures may be prognostic for predicting disease progression and recurrence.
Authors
- Michael A. Mederos (ORCID: https://orcid.org/0000-0001-8098-7746)
- Thomas G. Graeber (ORCID: https://orcid.org/0000-0001-8574-9181)
- Colin M. Court (ORCID: https://orcid.org/0000-0002-9357-8957)
- David W. Dawson (ORCID: https://orcid.org/0000-0002-0215-5861)
- Mark D. Girgis (ORCID: https://orcid.org/0000-0002-8085-4422)
- O. Joe Hines (ORCID: https://orcid.org/0000-0003-0517-781X)
- Timothy R. Donahue (ORCID: https://orcid.org/0000-0002-1175-2545)
- James S. Tomlinson (ORCID: https://orcid.org/0000-0002-8815-0518)
- Benjamin J. DiPardo
- Joseph R. Pisegna
Institutions
- California NanoSystems Institute (US)
- University of California, Los Angeles (US)
- The University of Texas at San Antonio Health Science Center (US)
- Veterans Health Administration (US)
- Mays Cancer Center at UT Health San Antonio (US)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1002/jso.27830
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- W. M. Keck Foundation
- Hirshberg Foundation for Pancreatic Cancer Research
- National Institutes of Health
- National Cancer Institute